Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs
Abstract Background Decisions relating to the funding of new drugs are becoming increasingly challenging due to a combination of aging populations, rapidly increasing list prices, and greater numbers of drug-indication pairs being brought to market. This is especially true in cancer, where rapid lis...
Prif Awduron: | , , , , , , |
---|---|
Fformat: | Erthygl |
Iaith: | English |
Cyhoeddwyd: |
BMC
2019-07-01
|
Cyfres: | BMC Public Health |
Pynciau: | |
Mynediad Ar-lein: | http://link.springer.com/article/10.1186/s12889-019-7303-2 |